P/B
3,6
Talphera
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
$52.4M
Market Cap • 11/2/2026
2005
(21 years)
Founded
2011
(15 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
52424,9
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,3
EPS
—
Market Cap
Market Cap
52,4M
EV
35,3M
EV/Revenue
35348,9
EV/EBITDA
-2,4
EV/EBIT
-2,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-42,3%
Total Yield
-42,3%
Payout
0%
Retained Earnings
-478,4M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
670400%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-79,9%
CAGR Op. Income 5Y
-17%
CAGR Net Income 5Y
-16,3%
CAGR EPS 5Y
-48,1%
CAGR OCF 5Y
-17,7%
Leverage
N.D./EBITDA
1,2
Debt/Equity
0%
Current Ratio
4,3
Quick Ratio
4,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!